Restarting antidepressant and antipsychotic medication after intentional overdoses: need for evidence-based guidance
Author(s) -
Tay Emma,
Sotiriou Andreas,
Graham Garry G.,
Wilhelm Kay,
Snowden Leone,
Day Richard O.
Publication year - 2019
Publication title -
therapeutic advances in psychopharmacology
Language(s) - English
Resource type - Journals
eISSN - 2045-1261
pISSN - 2045-1253
DOI - 10.1177/2045125319836889
Subject(s) - antipsychotic , medicine , antidepressant , drug overdose , pharmacology , adverse effect , drug , psychiatry , pharmacokinetics , intensive care medicine , schizophrenia (object oriented programming) , poison control , emergency medicine , anxiety
Intentional drug overdoses with antidepressant and antipsychotic medications are an increasingly common problem. Currently, there is little guidance with regard to reintroduction of these medications after intentional overdoses. We have used published toxicological and pharmacokinetic data to obtain factors which control the recovery from overdoses. From such data, we have proposed guidance regarding their reintroduction, provided there are no adverse effects or contraindications. Tentatively, we suggest that when adverse effects from the overdose are lost, treatment could recommence after a further mean half-life of elimination. Most antidepressant and antipsychotic drugs are metabolized by cytochrome P450 enzymes and, where cytochrome P450 inhibitors are co-ingested, serial plasma concentrations should optimally be obtained in order to assess a suitable time for reintroduction of the psychoactive drugs. We hope the proposals presented will stimulate research and discussion that lead to better guidance for clinicians concerning reintroduction of psychoactive medication after intentional overdose.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom